Schein, Jeff
Childress, Ann
Adams, Julie
Gagnon-Sanschagrin, Patrick
Maitland, Jessica
Qu, Wendi
Cloutier, Martin
Guérin, Annie
Article History
Received: 8 February 2022
Accepted: 28 July 2022
First Online: 18 August 2022
Declarations
:
: Data are de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act. This study does not contain any patient-identifiable information; therefore, no institutional review board exemption nor informed consent was required.
: Not applicable.
: JS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. AC received research support from Allergan, Takeda/Shire, Emalex, Akili, Ironshore, Arbor, Aevi Genomic Medicine, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, and the U.S. Food and Drug Administration; was on the advisory board of Takeda/Shire, Akili, Arbor, Cingulate, Ironshore, Neos Therapeutics, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, Supernus, and Corium; received consulting fees from Arbor, Ironshore, Neos Therapeutics, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, Corium, Jazz, Tulex Pharma, and Lumos Pharma; received speaker fees from Takeda/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Tris, and Supernus; and received writing support from Takeda /Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Purdue, Rhodes, Sunovion, and Tris. JA was an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. at the time of study conduct. PGS, JM, WQ, MC, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc.